Bringing science and development together through news and analysis

  • Genomics: the cure for Third World disease?

Shares
Developing countries stand to profit most from advances in genome science, say Samuel Broder (Celera Genomics), Stephen Hoffman (Sanaria) and Peter Hotez (George Washington University, United States), in this EMBO Reports viewpoint article. They claim that biotechnology coupled with genomics might emerge as the key technology for improving global health in the 21st century.

But the authors warn that developing-world diseases should no longer be viewed in purely medical or public health contexts. Infectious diseases are likely to pose a major risk to the economic survival of many developing nations. And recent studies suggest that some of these diseases may have wider implications for global security, with possible links to the probability that a nation will experience armed conflict.

Genomic research has already advanced our knowledge of infectious diseases, with the genome sequences of many pathogens now established. The authors say that the new tools of comparative genomics, computational biology, and informatics offer remarkable opportunities for reducing the negative impact of diseases in developing countries.

Link to full article

Reference: EMBO reports 3, 9, 806 (2002)
Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.